Skip to main content
. Author manuscript; available in PMC: 2019 Dec 17.
Published in final edited form as: Int J Cancer. 2019 Apr 8;146(3):617–626. doi: 10.1002/ijc.32268

Table 3:

3- and 5-year absolute risks of CIN3 and CIN2+, following one, two and three negative cotests, adjusted for unresolved positive results^

N 3-year risk of CIN3 5-year risk of CIN3 3-year risk of CIN2+ 5-year risk of CIN2+
Absolute
risk
95% CI Absolute
risk
95% CI Absolute
risk
95% CI Absolute
risk
95% CI
One negative co-test 174,205 0.025% (0.014, 0.036) 0.034% (0.023, 0.046) 0.061% (0.037, 0.085) 0.128% (0.101, 0.155)
Two negative co-tests 63,813 0.010% (0.000, 0.025) 0.041% (0.007, 0.076) 0.040% (0.019, 0.062) 0.092% (0.045, 0.139)
Three negative co-tests* 10,549 0.016% (0.000, 0.052) 0.016% (0.000, 0.052) 0.016% (0.000, 0.052) 0.016% (0.000, 0.052)

Confidence intervals are based on bootstrapping. No women were diagnosed with invasive cervical cancer

*

Based on one observed event

^

Assuming women with unresolved positive results are missing at random given their positive result, see Supplementary Materials 2 for details